Alchemab Therapeutics is a biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies. The company has developed a platform that enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires. The platform uses defined patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody responses in groups of individuals that are susceptible but resilient to specific diseases. In addition, Alchemab develops a broad pipeline of protective therapeutics for hard-to-treat diseases, with an initial focus on oncology, neurodegenerative conditions, and infectious diseases.